TOFACITINIB CITRATE
( DrugBank: Tofacitinib, Tofacitinib citrate / KEGG DRUG: Tofacitinib citrate, Tofacitinib, Tofacitinib citrate, Tofacitinib )
5 diseases
| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 73 |
| 49 | 全身性エリテマトーデス | 1 |
| 97 | 潰瘍性大腸炎 | 30 |
46. 悪性関節リウマチ
臨床試験数 : 4,743 / 薬物数 : 3,042 - (DrugBank : 389) / 標的遺伝子数 : 205 - 標的パスウェイ数 : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. 全身性エリテマトーデス
臨床試験数 : 1,414 / 薬物数 : 1,077 - (DrugBank : 181) / 標的遺伝子数 : 130 - 標的パスウェイ数 : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. 潰瘍性大腸炎
臨床試験数 : 3,566 / 薬物数 : 2,369 - (DrugBank : 339) / 標的遺伝子数 : 210 - 標的パスウェイ数 : 245
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
107. 若年性特発性関節炎
臨床試験数 : 500 / 薬物数 : 338 - (DrugBank : 52) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 157
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
271. 強直性脊椎炎
臨床試験数 : 631 / 薬物数 : 405 - (DrugBank : 73) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
